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Sir: Rapid onset of action, high
success rate, and a short half-life
are distinct advantages of adenosine
for converting paroxysmal supraven-
tricular tachycardia (SVT) to sinus
rhythm. While shorted-lived sensa-
tions of dyspnea and chest pain com-
monly accompany the administration
of adenosine, serious side effects are
fortunately infrequent and mostly
confined to cardiac arrhythmias and,
rarely, bronchospasm. Consequently,
higher grade AV blocks, sick sinus
syndrome, and asthma are listed
as contraindications for adenosine.
Salbutamol-induced SVT occurring
in the alert, spontaneously breathing
asthmatic patient thus constitutes
a therapeutic dilemma.
We report our experience in two
boys with salbutamol-induced SVT
who were successfully converted
with adenosine during asthma ex-
acerbations. Neither of them had
significant hypokalemia at the onset
of SVT. One boy with brittle asthma
had three episodes of SVT at 20, 22,
and 24 months of age during ther-
apy for status asthmaticus. The first
episode was considered salbutamol-
induced, and intravenous adenosine
at 0.1 mg/kg was successful in all
three instances without worsening
of his asthma. In all three episodes
he was receiving continuous inhal-
ations of salbutamol, the first two
while being mechanically venti-
lated in pressure-control mode. No
changes were noted in tidal vol-
umes. Unfortunately there was no
end-tidal CO2 monitor in place at
the time. The second boy suffered
a salbutamol-induced SVT during
an acute asthma exacerbation at
the age of 6 years. At the time of
the SVT episode he was awake,
tachypneic, and saturating around
88% with 6 l/min of oxygen by
facemask. No changes in respira-
tory parameters were observed after
SVT termination with 0.1 mg/kg
adenosine.
Although adenosine may be
safely administered in most children
with a history of asthma [1, 2], rare
case reports indicate that this drug
has a potential for inducing bron-
chospasm in vulnerable individuals.
Only two instances of adenosine
administration in acutely asthmatic
children with salbutamol-induced
SVT have been reported so far, both
apparently without adverse effects on
asthmatic symptoms [3, 4]. Our ex-
perience suggests that salbutamol
may provide protection from
adenosine-related worsening of
bronchospasm during asthma exacer-
bations.
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